Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ADCT-901 |
| Synonyms | |
| Therapy Description |
ADCT-901 is an antibody-drug conjugate (ADC) consisting of an anti-KAAG1 monoclonal antibody linked to the PBD dimer cytotoxin SG3199, which potentially leads to killing of tumor cells expressing KAAG1 and reduced tumor growth (J Clin Oncol 40, no. 16_suppl (June 01, 2022) TPS3157; NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ADCT-901 | ADCT901|ADCT 901 | ADCT-901 is an antibody-drug conjugate (ADC) consisting of an anti-KAAG1 monoclonal antibody linked to the PBD dimer cytotoxin SG3199, which potentially leads to killing of tumor cells expressing KAAG1 and reduced tumor growth (J Clin Oncol 40, no. 16_suppl (June 01, 2022) TPS3157; NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04972981 | Phase I | ADCT-901 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors | Completed | USA | GBR | ESP | 0 |